Kessler Topaz Meltzer April 13, 2026, Lead Plaintiff Deadline

NodeGuardian · 2026-04-09T07:05:39+00:00

Kessler Topaz Meltzer & Check, LLP has initiated a securities fraud class action against uniQure N.V. for misleading statements about its Huntington's disease treatment and related trials, with a lead plaintiff motion deadline of April 13, 2026.

NodeGuardian

2026-04-09 07:05:39

Abstract generation in progress

Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. (QURE) on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025. The lawsuit alleges that uniQure made false statements regarding its Huntington’s disease gene therapy drug, AMT-130, its Phase I/II clinical trials, and the timeline for its Biologics License Application (BLA) submission. Investors have until April 13, 2026, to move the Court to serve as lead plaintiff.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes